

Herbal Drugs of Abuse
***Glaucium flavum* and *Sceletium tortuosum*:**
Metabolism and toxicological detectability of their alkaloids
glaucine, mesembrine and mesembrenone
studied in rat urine and human liver preparations
using GC-MS, LC-MS, LC-HR-MSⁿ, and NMR

Dissertation
zur Erlangung des Grades
des Doktors der Naturwissenschaften
der Naturwissenschaftlich-Technischen Fakultät III -
Chemie, Pharmazie, Bio- und Werkstoffwissenschaften
der Universität des Saarlandes

Von
Golo Magnus Joris Onno Max Meyer

Saarbrücken

2014

Tag des Kolloquiums:	21.11.2014
Dekan:	Univ.-Prof. Dr.-Ing. Dirk Bähre
Berichterstatter:	Univ.-Prof. Dr. Dr. h.c. Hans H. Maurer Univ.-Prof. Dr. Rolf W. Hartmann
Vorsitz:	Univ.-Prof. Dr. Adolfo Cavalié
Akad. Mitarbeiter:	Dr. Josef Zapp

Die folgende Arbeit entstand unter der Anleitung von Herrn Professor Dr. Dr. h.c. Hans H. Maurer in der Abteilung Experimentelle und Klinische Toxikologie der Fachrichtung 2.4 Experimentelle und Klinische Pharmakologie und Toxikologie der Universität des Saarlandes in Homburg/Saar von Juni 2010 bis Januar 2014.

Mein besonderer Dank gilt:

Professor Hans H. Maurer für die Aufnahme in den Arbeitskreis und die damit erhaltene Möglichkeit zum Erlernen des Handwerkszeugs des wissenschaftlichen Arbeitens, das Vertrauen, den eigenen Ideen nachgehen zu können, die vielen Fachkongresse besuchen zu dürfen und der ständig offen stehenden Tür,

Professor Rolf W. Hartmann für die Übernahme des Koreferats,

Allen Kolleginnen und Kollegen für die schöne Zeit, Hilfe bei der Einarbeitung, insbesondere Dirk Wissenbach, Hilfe bei Versuchen, Vererbung von Fällen, Diskussionsbereitschaft,

Dr. Markus R. Meyer für die ständige Unterstützung zum eigenverantwortlichen Arbeiten aber auch für die Antworten, Einschätzungen und Bewertungen bei den zu diskutierenden Themen,

Armin Weber für seine permanente Hilfsbereitschaft und großes Engagement in allen fachlichen und privaten Angelegenheiten,

Gabriele Ulrich für die spannenden Rattenversuche und Carsten Schröder für technische Unterstützung und den künstlerischen Support sowie

Dr. Josef Zapp für die Aufnahme und Auswertung der NMR-Daten.

Meinen Eltern und meinem Bruder danke ich für die ständige Unterstützung in allen Lebenslagen und permanente Hilfsbereitschaft. Ohne Euch wäre ich nicht so weit gekommen.

Ganz besonders danke ich meiner Partnerin Aline Wangler für die Bereitschaft diesen teilweise etwas steinigen Weg mit mir zu gehen, die permanente Unterstützung, das Verständnis für die vielen Abwesenheiten und vor allem die starken Nerven.

Für die,
die es interessiert!

Phantasie ist wichtiger als Wissen,
denn Wissen ist begrenzt.

Albert Einstein

Table of Contents

1. General Part.....	6
1.1 Introduction.....	6
1.1.1 Herbal drugs of abuse as legal highs.....	6
1.1.2 Drug metabolism	7
1.1.3 <i>Glaucium flavum</i> alkaloid glaucine	7
1.1.4 <i>Sceletium tortuosum</i> alkaloids: mesembrine and mesembrenone.....	8
1.1.5 Synthesis of phase I metabolites of glaucine.....	10
1.1.6 Isolation of mesembrine and mesembrenone.....	10
1.1.7 Structure elucidation of the metabolites.....	11
1.1.8 Toxicological detection	11
1.2 Aims and scopes	13
2. Publication of the results.....	14
2.1 Studies on the metabolism and toxicological detection of glaucine, an isoquinoline alkaloid from <i>Glaucium flavum</i> (Papaveraceae), in rat urine using GC-MS, LC-MS(n) and LC-high-resolution MS(n) [15] (DOI: 10.1002/jms.3112).....	14
2.2 Studies on the in vivo contribution of human cytochrome P450s to the hepatic metabolism of glaucine, a new drug of abuse [25] (DOI: 10.1016/j.bcp.2013.08.025)	16
2.3 GC-MS, LC-MSn, LC-high resolution-MSn, and NMR studies on the metabolism and toxicological detection of mesembrine and mesembrenone, the main alkaloids of the legal high “Kanna” isolated from <i>Sceletium tortuosum</i> [62] (DOI: 10.1007/s00216-014-8109-9).....	18
3. Conclusion.....	19
4. Summary	21
5. References	22
6. Abbreviations	28
7. Zusammenfassung.....	30

1. General Part

1.1 Introduction

1.1.1 Herbal drugs of abuse as legal highs

Since the implementation of the opium law in the 1960s by the United Nations (UN), modern societies tried to control the illicit drug market for reasons of health and to protect the community from outgrowths like drug-related crime. The legislative process is superior organized by the UN, but every associated country has to execute its national depended narcotic acts by its own. In Germany and in many other countries (e.g. USA, Switzerland, France), the substances controlled by state were defined in form of a whitelist. Consequently, every substance or plant species named by this list is a “controlled substance”. In the first four decades, only few substances were controlled and the illicit drug market was very stable. For example in the 1970s, consumption of LSD and THC was the new trend, in the 1980s, heroin became popular, and in the 1990s, MDMA and amphetamine. At the beginning of the 21st century, analogue structures were developed to circumvent the legislative process. For instance, different derivatives of synthetic cannabinoids (Spice), amphetamines, phenethylamines, and cathinones were put on the market [1-9]. These chemicals were sold via the internet as bath salts, plant fertilizers, or party pills. Being not (yet) scheduled, they were called “legal highs”. These legal highs are single compounds or mixtures of different compounds with more or less strong psychoactive effects [7], but without declared ingredients. In addition, different old or new “herbal highs” from natural source, often plant species from other cultures, were available in the age of globalization. Especially due to the internet advertisement and the availability in the trade in goods all around the world, the number of new herbal highs increased in the last few years. Examples were magic mushrooms, different cactus species, Ayahuasca, baby woodrose (*Argyreia nervosa*) seeds, Kratom (*Mitragyna speciosa*), yellow hornpoppy (*Glaucium flavum*), and Kanna (*Sceletium tortuosum*) [3, 7, 10-14]. Different preparations such as herbs, extracts, tinctures, as well as fresh plant material were offered from single plant species or mixtures. Mostly, the identity of such preparations is not confirmed and their pharmacological and toxic effects as well as their pharmacokinetic behavior are unknown. Therefore, studies on the metabolism and detectability of the metabolites in body samples of such “herbal highs” play an important role in clinical and forensic toxicology.

1.1.2 Drug metabolism

Besides the endogenous metabolism, the metabolism of xenobiotics plays an important role in biochemistry and toxicology. The metabolizing enzymes are not selective and transform various endogenous and exogenous compounds. The resulting metabolites can be pharmacologically and toxicologically inactive (biodeactivation/detoxification) or active (bioactivation/toxification). Most of these reactions are oxidative reactions, which result in increasing hydrophilic properties, which facilitate the renal elimination of these compounds. Not all reactions increase hydrophilicity, for example, methylation catalyzed by the catechol-O-methyltransferase (COMT) leads to increased lipophilicity. The metabolic steps are divided in phase I reactions (functionalization) and phase II reactions (conjugation with e.g. glucuronic, sulfuric, or amino acids).

The characterization of the metabolic fate of xenobiotics is important in clinical and forensic toxicology for development of metabolite-based screening approaches [15-18] and for assessing the risk of pharmacokinetic interactions or pharmacogenomic variations in the effect. In contrast to medicaments, such studies are missing for drugs of abuse before consumption. Different in vitro assays and animal models can be used for elucidation of the metabolic fate. For example, rat species provide a metabolite pattern (qualitatively) similar to humans [2, 19, 20]. These data should be confirmed e.g. by in vitro assay with human recombinant enzymes, liver preparations, or hepatocytes. Recombinant enzymes allow studying the formation kinetics of single enzymes [21-24]. For determination of such enzyme kinetics, the formed metabolite or the degradation of the substrate must be quantified [25]. For quantification of the formed metabolites, reference standards are needed. In most cases, especially for new drugs of abuse, such reference standards are commercially not available. One opportunity is the chemical [25] or biochemical synthesis [26-28] of metabolites. If not possible and only one metabolite is formed by the particular enzyme, a substrate depletion approach can be used [25, 29-31]. However, arbitrary units (e.g. the ratio of the LC-MS peak area of the formed metabolite vs. that of an internal standard) can also be used for assessing K_m , but not for V_{max} values.

1.1.3 *Glaucium flavum* alkaloid glaucine

Glaucine ((S)-5,6,6a,7-tetrahydro-1,2,9,10-tetramethoxy-6-methyl-4H-dibenzo[de,g]quinoline, structure given in Fig. 1) is an isoquinoline alkaloid with aporphine structure and main ingredient of *Glaucium flavum* (yellow hornpoppy, Papaveraceae). Other

glaucine containing plant species are: *Glaucium oxylobum*, *Croton lechlen*, *Corydalis yanhusu*, *Nandina domestica* [32-36]. Yellow hornpoppy is native in Western Europe, North America, and Asia. The latex, typical for *Papaveraceae*, contains the main alkaloids in varying concentration (up to 3 %) depending on environmental factors, species variations and plant parts such as root, stem or leave [35]. Other alkaloids of yellow hornpoppy are protopine, chelerythrine, magnoflorine, and other minor ones [37].




Fig. 1 Structure of glaucine

Glaucine has anti-inflammatory and antitussive properties, acts as a phosphodiesterase-4 (PDE4) inhibitor, bronchodilator, calcium channel blocker, and weak dopamine D₁ and D₂ receptor antagonist [38, 39]. The antitussive properties of glaucine in humans were investigated in three different clinical studies in comparison to codeine or dextromethorphan [40]. Glaucine showed a comparable decrement in cough besides less adverse effects and no signs of opiate withdrawal after longer intake [41]. On the other hand, case reports of recreational use [42, 43] or side effects of therapeutic use [10] are described and show the following symptoms: feeling of tiredness, hallucinations, vomiting, dizziness, and decreased blood pressure. Besides its use as antitussive e.g. in Bulgaria and Poland, glaucine is part of misused party pills or legal highs [10, 42].

1.1.4 *Sceletium tortuosum* alkaloids: mesembrine and mesembrenone

Sceletium tortuosum belongs to the plant family of *Aizoaceae*, which is mainly distributed in South Africa [44]. Besides the main alkaloids mesembrine ((3aR,7aR)-3a-(3,4-dimethoxyphenyl)-1-methyloctahydro-6H-indol-6-one) and mesembrenone ((3aR,7aS)-

3a-(3,4-dimethoxyphenyl)-1-methyl-1,2,3,3a,7,7a-hexahydro-6H-indol-6-one, structures given in Fig. 2), several structurally similar compounds were described in the literature, for example Δ^7 -mesembrenone, mesembranol, mesembrenol, tortuosamine, sceletium alkaloid A4 etc. [44-46]. These alkaloids were also identified in other *Mesembryanthemaceae* species [44, 45]. The total alkaloid content in *Mesembryanthemaceae* species is very low (1-1.5 %), but *Sceletium tortuosum* showed the highest levels [47]. Geographic and/or growing conditions, age of the plants, as well as the process of fermentation influence the alkaloid content and/or composition [48].




Fig. 2 Structures of mesembrine (A) and mesembrenone (B)

The KhoiSan, previously known as Hottentots, a tribe in South Africa, used the plant species after fermentation for their psychoactive effects [47, 48]. The alkaloids were tested by Harvey et al. in receptor and enzyme binding studies as well as in cell assays [49]. An ethanolic extract showed strong inhibition of 5-HT transporters (IC_{50} , 4.3 μ g/mL) and of the PDE-4, (IC_{50} , 8.5 μ g/mL). Further experiments concluded that mesembrine had the lowest K_i value (1.4 nM) for the 5-HT transporter, whereas mesembrenone showed the strongest inhibition effects against the PDE-4 (IC_{50} , <1 μ M). Further clinical trials and experiments in humans confirmed these findings with antidepressive and anxiolytic effects of the extract [50, 51]. Khan et al. characterized the pharmacological activity of an extract of *Sceletium tortuosum* and mesembrine itself in Sprague-Dawley rats by conditioned place preference, hot plate, forced swim, elevated plus, and rotarod tests [52] for elucidating effects on nociception, depression, anxiety, ataxia, abuse liability. Differences between the single compound mesembrine and the administration of a plant extract containing several other substances were also tested. Mesembrine

caused analgesia, without abuse liabilities or ataxia, whereas the rats treated with the extract had higher tendency to fall from the rotating drum (ataxia), and showed higher activity swimming behavior (antidepressant activity) in the forced swim test. The authors interpreted these findings with the presence of further pharmacological active compounds in the extract, which were corresponding to the observed effects.

Besides the medical or traditional use, different Kanna or “Kougoed” preparations such as fermented and dried herbs, powders, capsules, extracts were administered by chewing, smoking, or sniffing. The preparations are available in so-called smart shops and are misused as legal highs [7].

1.1.5 Synthesis of phase I metabolites of glaucine

Due to the four methoxy and the *N*-methyl groups of glaucine, five isomeric demethyl metabolites could be expected as phase I metabolites. Reference standards of these metabolites were commercially not available and had to be synthesized. Full synthesis of such complex structures would have been too complicated, time consuming and expensive. Therefore, less complicated semi-synthesis by demethylation or methylation reactions of related structures was an alternative route of synthesis [53-56]. Non-selective reactions would yield in a complex mixture of isomers, which had to be isolated after synthesis. Hence, selective reactions could overcome these problems. In the literature, different selective *N*- or *O*-demethylation reactions were described for other substances [54-56]. An alternative route is the methylation of the phenolic compound boldine (2,9-dihydroxy-1,10-dimethoxyaporphine) [53], the main alkaloid of the boldo tree (*Peumus boldus*, *Monimiaceae*) [57], which was commercial available.

The corresponding syntheses were described in ref. [25] (see chapter 2.2)

1.1.6 Isolation of mesembrine and mesembrenone

In the literature, synthesis or isolation procedures for mesembrine and mesembrenone have been described [58-61]. The advantage of isolation from plant material was the possibility of yielding the main as well as the minor alkaloids in one step. In addition, the isolated compounds from plant material have the correct absolute configuration, which is not always achieved by chemical synthesis. So far, only few isolation procedures were described [60, 61]. Shikanga et al. described a method by using high-speed countercurrent chromatography (HSCCC) for the isolation of *Sceletium* alkaloids [61].

The all-liquid technique might avoid the reported irreversible absorption effects on packing material using column chromatography. In case of using acidic silica as stationary phase, these absorption effects led to strong tailing effects and therefore, to insufficient separation of the alkaloids [61]. Nevertheless, the authors separated the alkaloid extract after liquid-liquid extraction (LLE) by column chromatography (CC) with silica before separating the CC-fraction with HSCCC [61].

The adsorption effects on the silica packing material in CC might be avoided by using basic aluminum oxide as stationary phase. Hence, the more easily conducted CC might be effective enough to separate the alkaloids in acceptable yield, time and effort. To improve the overall yield of isolated alkaloids, the basic LLE were replaced using a Soxhlet apparatus, which allowed an exhaustive extraction.

The corresponding isolation was described in ref. [62] (see chapter 2.3)

1.1.7 Structure elucidation of the metabolites

For structure elucidation of unknown compounds, different analytical techniques can be used such as UV/VIS, IR, NMR, and MS [63]. Each technique has its advantages and disadvantages. The choice of the technique mainly depends on compound chemistry, the matrix, and the concentration therein. For identification of pure substances, all these techniques can be applied in parallel. In case of structure elucidations in drug metabolism studies, the application of different gas chromatographic (GC) or liquid chromatography (LC) techniques coupled to low or high resolution mass spectrometry (LR-MS or HR-MS) provide several advantages, such as high sensitivity and detailed structure information by the fragmentation patterns [64-68]. However, the exact position of a metabolically introduced or changed substituent cannot be elucidated. NMR would provide this information, but cannot be used for the low concentrated metabolites in biomatrix. Thus, only chemical synthesis of the proposed metabolites would help in this case.

The identification of the metabolites of the studied alkaloids was described in refs. [15, 62] (see chapters 2.1 and 2.3).

1.1.8 Toxicological detection

The detection of new drugs or legal highs in body samples of patients, victims, or suspects is a major challenge in clinical and forensic toxicology [5, 17, 20, 69, 70]. Urine

screening is the most comprehensive approach covering a broad range of (also low dosed) drugs for a longer time than blood, but mostly the metabolites are the analytical targets. Thus, the metabolism and the detectability of new drugs in urine have to be studied. After having elucidated the metabolite structures after high dose drug application and 24 h urine collection, their detectability in rat urine after a common user's dose using the standard urine screening approaches (SUSA) can be assessed [17, 20].

The detectability in urine of the studied alkaloids was described in refs. [15, 62] (see chapters 2.1 and 2.3).

1.2 Aims and scopes

So far, there are no studies available describing the metabolism of *Glaucium flavum* alkaloid glaucine or the *Sceletium tortuosum* alkaloids mesembrine and mesembrenone. Therefore, the aims of the presented study were:

- Identification of the phase I and II metabolites of glaucine in rat urine using GC-MS and LC-HR-MSⁿ
- Investigation of the detectability of glaucine by the standard urine screening approaches
- Confirmation of the phase I metabolites in human liver preparations and identification of the involved cytochrome P450 (CYP) isoenzymes
- Synthesis of the phase I metabolites of glaucine for structure confirmation and as reference standards for quantitative *in vitro* enzyme kinetics
- Determination of the CYP enzyme kinetics of glaucine in heterologically expressed single CYPs and in HLM and comparison of the results obtained by determination of the synthesized metabolites and using arbitrary units
- Isolation of mesembrine and mesembrenone from *Sceletium tortuosum* as reference standards for metabolism studies
- Identification of the phase I and II metabolites of mesembrine and mesembrenone in rat urine using GC-MS and LC-HR-MSⁿ
- Confirmation of the phase I metabolites of mesembrine and mesembrenone in human liver preparations and identification of the involved CYP isoenzymes
- Investigation of the detectability of mesembrine and mesembrenone by the standard urine screening approaches

2. Publication of the results

The results of the studies were published in the following papers:

- 2.1 Studies on the metabolism and toxicological detection of glaucine, an isoquinoline alkaloid from *Glaucium flavum* (Papaveraceae), in rat urine using GC-MS, LC-MS(n) and LC-high-resolution MS(n) [15] (DOI: 10.1002/jms.3112)**

**2.2 Studies on the in vivo contribution of human cytochrome P450s to the hepatic metabolism of glaucine, a new drug of abuse [25]
(DOI: 10.1016/j.bcp.2013.08.025)**

**2.3 GC-MS, LC-MSn, LC-high resolution-MSn, and NMR studies on the metabolism and toxicological detection of mesembrine and mesembrenone, the main alkaloids of the legal high “Kanna” isolated from *Sceletium tortuosum* [62]
(DOI: 10.1007/s00216-014-8109-9)**

3. Conclusion

The presented studies have shown that glaucine was extensively metabolized in rat by *O*- and *N*-demethylation, *N*-oxidation, hydroxylation, combinations of them as well as glucuronidation and/or sulfation of the phenolic metabolites [15]. In total, 26 phase I and 21 phase II metabolites could be identified. The synthesized demethylated metabolites, the structures of which were confirmed by NMR, allowed their identification in urine extracts by comparing their chromatographic retention times and mass spectra. The demethylated metabolites were also identified to be the main targets in both toxicological urine screening approaches [17, 20]. An intake of glaucine could be monitored in rat urine after administration of 2 mg/kg body mass (BM), corresponding to a 40 mg human single cough medication dose scaled by dose-by-factor approach according to ref. [71]. Using the GC-MS approach, the acetylated mono- and bis-demethylated metabolites could be detected whereas in the LC-MSⁿ screening approach the demethylated metabolites and their glucuronides were the analytical targets. The further *in vitro* studies with HLM confirmed the formation of the mono-demethylated metabolites in humans [25]. The involved CYP isoforms in the enzymatic demethylation of glaucine were as follows: CYP1A2, CYP2C19, CYP2D6, CYP3A4, and CYP3A5. All kinetic profiles could be modeled using the Michaelis-Menten equation. For all enzyme kinetics (CYPs, HLM), the metabolite formation approach using calibration with the corresponding synthesized reference standards was applied and compared to the results to those obtained by arbitrary units. The bias of the quantification approach for assessing the contribution of CYPs to hepatic clearance and therefore to the hepatic net clearance *in vivo* was negligible. In conclusion, the determination method had no substantial impact on the estimation of *in vivo* hepatic clearance of glaucine. Further inhibition experiments in HLM with specific and selective inhibitors confirmed the results of the contribution of the involved CYPs. Using the Michaelis-Menten equation and determined pharmacokinetic constants, concentration-dependent involvement of CYP isoforms was calculated for different glaucine concentrations (0.1-100 μ M) according to Meyer et al. [72]. In a case report of recreational glaucine use [42], plasma levels of 0.7 mg/L (2 μ M) were documented. Over the tested concentration range, only minor variations in the enzyme contributions were observed. The overall contribution of all CYP-catalyzed metabolic steps was as follow: CYP3A4 was about 79 %, of CYP1A2 18 %, of CYP2D6 2 %, and of CYP2C19 <1 % determined for a glaucine concentration of 5 μ M. As glaucine was metabolized via three main steps and different CYP isoforms were

involved in the hepatic clearance of glaucine, a clinically relevant interaction with single inhibitors should not be expected. Over the last years, many studies have been published regarding the impact of interactions with drugs of abuse, therapeutically administered drugs, food ingredients, and/or tobacco smoke ingredients as well as of genetic variations [2, 73-75]. For assessment or prediction of all these variations, it is important to know whether an individual has a reduced or an increased turnover in these steps due to genetic variations or due to drug/food interactions by enzyme inhibition or induction. Such interactions are of general interest also in drug abuse because many drug users suffer from polytoxicomania with higher risk of drug interactions. Clinical or case studies are necessary for final assessment of the clinical relevance.

The developed isolation method for the Sceletium alkaloids allows simple and effective extraction and purification of both main alkaloids mesembrine and mesembrenone [62, 75]. The presented metabolism study has shown that mesembrine and mesembrenone were extensively metabolized by hydroxylation, dealkylation, dihydration, *N*-oxidation, and combinations of them. The main metabolites were confirmed in human liver preparations (HLM, HLC) and the following CYPs were determined: *O*-demethylation of mesembrine was catalyzed by CYP1A2, CYP2B6, CYP2C19, and CYP2D6 and the *N*-demethylation by CYP1A2, CYP2B6, CYP2C19, CYP2D6, CYP3A4, and CYP3A5. The *O*-demethylation of mesembrenone was catalyzed by CYP2C9, CYP2C19, and CYP2D6 and the *N*-demethylation by CYP2C19, CYP2D6, and CYP3A4 [62]. For the detectability studies, a 1 mg/kg BM dose were administered to rat and the urine was collected over a 24 h period. Using the GC-MS screening approach, the acetylated demethyl-dihydro and hydroxy metabolite of mesembrine, and the acetylated demethyl-dihydro mesembrenone metabolite could be detected. The main targets in the LC-MSⁿ screening approach for mesembrine were also the *O*- and *N*-demethyl-dihydro, and the *bis*-demethyl-dihydro metabolites, for mesembrenone only the *N*-demethyl- and the *N*-demethyl-dihydro metabolite and in addition their glucuronides.

4. Summary

In the presented studies, the metabolism and the toxicological detection of glaucine and the *Sceletium tortuosum* alkaloids mesembrine and mesembrenone were investigated. Glaucine was mainly O- and N-dealkylated in rats and further conjugated to glucuronides or sulfates. The phase I metabolites were synthesized and further in vitro experiments with HLM confirmed the formation of the metabolites in humans. The following CYP isoforms were mainly involved in these reactions: 1A2, 2C19, 2D6, 3A4, and 3A5. The kinetic profiles of all metabolite formations followed classic Michaelis-Menten behavior. The K_m values were between 25-140 μM and the V_{max} values between 0.10 - 1.92 pmol/min/pmol. Toxicological detection should be focused on the demethyl-dehydro metabolites and the corresponding glucuronides and/or sulfates.

Mesembrine and mesembrenone were also extensively metabolized in rat. The main metabolic pathway is a combination of demethylation and reduction of the keto function. The phenolic metabolites were partly excreted as glucuronides or sulfates. The phase I metabolites could also be found in human liver preparations. Demethylation of mesembrine was catalyzed by following CYPs: 1A2, 2B6, 2C19, 2D6, and 3A4 and the demethylation of mesembrenone by 2C9, 2C19, 2D6, and 3A4. The main analytical targets for the toxicological detection were the demethyl-dehydro metabolites and in case of LC-MSⁿ, the corresponding glucuronides and/or sulfates.

5. References

1. Brandt SD, Sumnall HR, Measham F, Cole J (2010) Analyses of second-generation 'legal highs' in the UK: initial findings. *Drug Test Anal* 2:377-382
2. Meyer MR, Maurer HH (2010) Metabolism of designer drugs of abuse: An updated review [review]. *Curr Drug Metab* 11:468-482
3. Meyer MR, Maurer HH (2011) Neue Designer-Drogen: Chemie, Pharmakologie und Metabolismus. *Suchtmed* 14:29-38
4. Schmidt MM, Sharma A, Schifano F, Feinmann C (2011) "Legal highs" on the net-Evaluation of UK-based Websites, products and product information. *Forensic Sci Int* 206:92-97
5. Brandt SD, Freeman S, Sumnall HR, Measham F, Cole J (2011) Analysis of NRG 'legal highs' in the UK: identification and formation of novel cathinones. *Drug Test Anal* 3:569-575
6. Baron M, Elie M, Elie L (2011) An analysis of legal highs: do they contain what it says on the tin? *Drug Test Anal* 3:576-581
7. Gibbons S (2012) 'Legal highs'--novel and emerging psychoactive drugs: a chemical overview for the toxicologist. *Clin Toxicol (Phila)* 50:15-24
8. Zuba D (2012) Identification of cathinones and other active components of 'legal highs' by mass spectrometric methods. *Trends Anal Chem* 32:12-30
9. Zuba D, Byrska B (2013) Prevalence and co-existence of active components of 'legal highs'. *Drug Test Anal* 5:420-429
10. Geppert B, Wachowiak R, Zaba C (2010) Glaucine as a non-declared active component of "Legal Highs". *Problems Forensic Sci* 84:401-408
11. Drug Enforcement Administration - Office of Forensic Sciences (2005) Herbal Drug Update: Kratom. *Microgram* 38:114-115
12. Babu KM, McCurdy CR, Boyer EW (2008) Opioid receptors and legal highs: *Salvia divinorum* and Kratom. *Clin Toxicol (Phila)* 46:146-152
13. Philipp AA, Zoerntlein SW, Klein ON, Maurer HH (2008) Studies on the metabolism and toxicological analysis of mitragynine, an ingredient of the herbal drug Kratom, in rat urine using GC-MS techniques. Abstract book to the 46th International TIAFT Meeting in La Martinique, June 2-7, 2008 129
14. Meyer MR, Caspar A, Brandt SD, Maurer HH (2014) A qualitative/quantitative approach for the detection of 37 tryptamine-derived designer drugs, 5 beta-carbolines, ibogaine, and yohimbine in human urine and plasma using standard urine screening and multi-analyte approaches. *Anal Bioanal Chem* 406:225-237

15. Meyer GMJ, Meyer MR, Wissenbach DK, Maurer HH (2013) Studies on the metabolism and toxicological detection of glaucine, an isoquinoline alkaloid from *Glaucium flavum* (Papaveraceae), in rat urine using GC-MS, LC-MSn and LC-high-resolution MSn. *J Mass Spectrom* 48:24-41
16. Maurer, H. H., Pflieger, K., and Weber, A. A.(2011) *Mass Spectral Library of Drugs, Poisons, Pesticides, Pollutants and their Metabolites*. Wiley-VCH, Weinheim (Germany)
17. Wissenbach DK, Meyer MR, Remane D, Weber AA, Maurer HH (2011) Development of the first metabolite-based LC-MSn urine drug screening procedure - exemplified for antidepressants. *Anal Bioanal Chem* 400:79-88
18. Maurer, H. H., Wissenbach, D. K., and Weber, A. A.(2014) *Maurer/Wissenbach/Weber MWW LC-MSn Library of Drugs, Poisons, and their Metabolites*. Wiley-VCH, Weinheim
19. Staack RF, Maurer HH (2005) Metabolism of Designer Drugs of Abuse [review]. *Curr Drug Metab* 6:259-274
20. Maurer, H. H., Pflieger, K., and Weber, A. A.(2011) *Mass Spectral and GC Data of Drugs, Poisons, Pesticides, Pollutants and their Metabolites*. Wiley-VCH, Weinheim (Germany)
21. Gillam EM (1998) Human cytochrome P450 enzymes expressed in bacteria: reagents to probe molecular interactions in toxicology. *Clin Exp Pharmacol Physiol* 25:877-886
22. Masimirembwa CM, Otter C, Berg M, Jonsson M, Leidvik B, Jonsson E, Johansson T, Backman A, Edlund A, Andersson TB (1999) Heterologous expression and kinetic characterization of human cytochromes P-450: validation of a pharmaceutical tool for drug metabolism research. *Drug Metab Dispos* 27:1117-1122
23. Walsky RL, Obach RS (2004) Validated assays for human cytochrome P450 activities. *Drug Metab Dispos* 32:647-660
24. Youdim K, Dodia R (2010) Comparison between recombinant P450s and human liver microsomes in the determination of cytochrome P450 Michaelis-Menten constants. *Xenobiotica* 40:235-244
25. Meyer GMJ, Meyer MR, Wink CSD, Zapp J, Maurer HH (2013) Studies on the in vivo contribution of human cytochrome P450s to the hepatic metabolism of glaucine, a new drug of abuse. *Biochem Pharmacol* 86:1497-1506
26. Peters FT, Bureik M, Maurer HH (2009) Biotechnological synthesis of drug metabolites using human cytochrome P450 isozymes heterologously expressed in fission yeast. *Bioanalysis* 1:821-830
27. Zollner A, Buchheit D, Meyer MR, Maurer HH, Peters FT, Bureik M (2010) Production of human phase 1 and 2 metabolites by whole-cell biotransformation with recombinant microbes. *Bioanalysis* 2:1277-1290

28. Dragan CA, Peters FT, Bour P, Schaan SM, Neunzig I, Widjaja M, Zapp J, Maurer HH, Bureik M (2011) Convenient gram-scale metabolite synthesis by engineered fission yeast strains expressing functional human P450 systems. *Appl Microbiol Biotechnol* 163:965-980
29. Obach RS, Reed-Hagen AE (2002) Measurement of Michaelis constants for cytochrome P450-mediated biotransformation reactions using a substrate depletion approach. *Drug Metab Dispos* 30:831-837
30. Nath A, Atkins WM (2006) A theoretical validation of the substrate depletion approach to determining kinetic parameters. *Drug Metab Dispos* 34:1433-1435
31. Schwaninger AE, Meyer MR, Maurer HH (2011) Investigation on the enantioselectivity of the sulfation of the methylenedioxymethamphetamine (MDMA) metabolites 3,4-dihydroxymethamphetamine (DHMA) and 4-hydroxy-3-methoxymethamphetamine (HMMA) using the substrate depletion approach. *Drug Metab Dispos* 39:1998-2002
32. Milanowski DJ, Winter RE, Elvin-Lewis MP, Lewis WH (2002) Geographic distribution of three alkaloid chemotypes of *Croton lechleri*. *J Nat Prod* 65:814-819
33. Morteza-Semnani K, Amin G, Shidfar MR, Hadizadeh H, Shafiee A (2003) Antifungal activity of the methanolic extract and alkaloids of *Glaucium oxylobum*. *Fitoterapia* 74:493-496
34. Xu XH, Yu GD, Wang ZT (2004) [Resource investigation and quality evaluation on wild *Corydalis yanhussuo*]. *Zhongguo Zhong Yao Za Zhi* 29:399-401
35. Petitto V, Serafini M, Gallo FR, Multari G, Nicoletti M (2010) Alkaloids from *Glaucium flavum* from Sardinia. *Nat Prod Res* 24:1033-1035
36. Peng CY, Liu JQ, Zhang R, Shu JC (2014) A new alkaloid from the fruit of *Nandina domestica* Thunb. *Nat Prod Res* 28:1159-1164
37. Daskalova E, Iskrenova E, Kiryakov H G, Evstatieva L (1987) Minor Alkaloids of *Glaucium flavum*. *Phytochem* 27:953-955
38. Cortijo J, Villagrasa V, Pons R, Berto L, Marti-Cabrera M, Martinez-Losa M, Domenech T, Beleta J, Morcillo EJ (1999) Bronchodilator and anti-inflammatory activities of glaucine: In vitro studies in human airway smooth muscle and polymorphonuclear leukocytes. *Br J Pharmacol* 127:1641-1651
39. Asencio M, Hurtado-Guzman C, Lopez JJ, Cassels BK, Protais P, Chagraoui A (2005) Structure-affinity relationships of halogenated predi-centrine and glaucine derivatives at D1 and D2 dopaminergic receptors: halogenation and D1 receptor selectivity. *Bioorg Med Chem* 13:3699-3704
40. Dicpinigaitis PV, Morice AH, Birring SS, McGarvey L, Smith JA, Canning BJ, Page CP (2014) Antitussive drugs--past, present, and future. *Pharmacol Rev* 66:468-512

41. Zhang A, Zhang Y, Branfman AR, Baldessarini RJ, Neumeyer JL (2007) Advances in development of dopaminergic aporphinoids. *J Med Chem* 50:171-181
42. Dargan PI, Button J, Hawkins L, Archer JR, Ovaska H, Lidder S, Ramsey J, Holt DW, Wood DM (2008) Detection of the pharmaceutical agent glaucine as a recreational drug. *Eur J Clin Pharmacol* 64:553-554
43. Lidder S, Dargan P, Sexton M, Button J, Ramsey J, Holt D, Wood D (2008) Cardiovascular toxicity associated with recreational use of diphenylprolinol (diphenyl-2-pyrrolidinemethanol [D2PM]). *J Med Toxicol* 4:167-169
44. Smith MT, Field CR, Crouch NR, Hirst M (1998) The distribution of mesembrine alkaloids in selected taxa of Kanna and their modification in the sceletium derived 'Kougoed'. *Pharmac Biol* 36:173-179
45. Roscher J, Posch TN, Putz M, Huhn C (2012) Forensic analysis of mesembrine alkaloids in *Sceletium tortuosum* by nonaqueous capillary electrophoresis mass spectrometry. *Electrophoresis* 33:1567-1570
46. Martin NH, Rosenthal D, Jeffs PW (1976) Mass spectra of *Sceletium* alkaloids. *Organic Mass Spectrom* 11:1-19
47. Smith MT, Crouch NR, Gericke N, Hirst M (1996) Psychoactive constituents of the genus *Sceletium* N.E.Br. and other Mesembryanthemaceae: a review. *J Ethnopharmacol* 50:119-130
48. Patnala S, Kanfer I (2009) Investigations of the phytochemical content of *Sceletium tortuosum* following the preparation of "Kougoed" by fermentation of plant material. *J Ethnopharmacol* 121:86-91
49. Harvey AL, Young LC, Viljoen AM, Gericke NP (2011) Pharmacological actions of the South African medicinal and functional food plant *Sceletium tortuosum* and its principal alkaloids. *J Ethnopharmacol* 137:1124-1129
50. Nell H, Siebert M, Chellan P, Gericke N (2013) A randomized, double-blind, parallel-group, placebo-controlled trial of Extract *Sceletium tortuosum* (Zembrin) in healthy adults. *J Altern Complement Med* 19:898-904
51. Terburg D, Syal S, Rosenberger LA, Heany S, Phillips N, Gericke N, Stein DJ, van HJ (2013) Acute effects of *Sceletium tortuosum* (Zembrin), a dual 5-HT reuptake and PDE4 inhibitor, in the human amygdala and its connection to the hypothalamus. *Neuropsychopharmacology* 38:2708-2716
52. Loria MJ, Ali Z, Abe N, Sufka KJ, Khan IA (2014) Effects of *Sceletium tortuosum* in rats. *J Ethnopharmacol* 155:731-735
53. Asencio M, Cassels B K, Speisky H (1993) The Methylation of Boldine with Diazomethane. *Bol Soc Chil Quim* 38:331-334

54. Ahmad R, Saa JM, Cava MP (1977) Regioselective O-demethylation in the aporphine alkaloid series. *J Org Chem* 42:1228-1230
55. Kok GB, Pye CC, Singer RD, Scammells PJ (2010) Two-step iron(0)-mediated N-demethylation of N-methyl alkaloids. *J Org Chem* 75:4806-4811
56. Kok GB, Scammells PJ (2011) Further investigations into the N-demethylation of oripavine using iron and stainless steel. *Org Biomol Chem* 9:1008-1011
57. Vogel H, Razmilic I, Munoz M, Doll U, Martin JS (1999) Studies of Genetic Variation of Essential Oil and Alkaloid Content in Boldo (*Peumus boldus*). *Planta Med* 65:90-91
58. Chavan SP, Khobragade DA, Pathak AB, Kalkote UR (2004) A simple and efficient synthesis of ($\pm$)-mesembrine. *Tetrahedron Lett* 45:5263-5265
59. Geoghegan K, Evans P (2013) Double reduction of cyclic aromatic sulfonamides: synthesis of (+)-mesembrine and (+)-mesembranol. *J Org Chem* 78:3410-3415
60. Jeffs PW, Capps T, Johnson DB, Karle JM, Martin NH, Rauckman B (1974) Sceletium alkaloids. VI. Minor alkaloids of *S. namaquense* and *S. strictum*. *J Org Chem* 39:2703-2710
61. Shikanga EA, Viljoen A, Combrinck S, Marston A (2011) Isolation of Sceletium alkaloids by high-speed countercurrent chromatography. *Phytochem Lett* 4:190-193
62. Meyer GMJ, Wink CSD, Zappia L, Maurer HH (2014) GC-MS, LC-MSⁿ, LC-high resolution-MSⁿ, and NMR studies on the metabolism and toxicological detection of mesembrine and mesembrenone, the main alkaloids of the legal high "Kanna" isolated from *Sceletium tortuosum*. *Anal Bioanal Chem*. DOI: 10.1007/s00216-014-8109-9
63. Hesse, M., Meier, H., and Zeeh, B.(2011) *Spektroskopische Methoden in der organischen Chemie*. Thieme, Stuttgart
64. Wagner DS, Pirhalla JL, Bowers GD (2013) Metabolite structure analysis by high-resolution MS: supporting drug-development studies. *Bioanalysis* 5:463-479
65. Meyer MR, Maurer HH (2012) Current status of hyphenated mass spectrometry in studies of the metabolism of drugs of abuse, including doping agents [review]. *Anal Bioanal Chem* 402:195-208
66. Huang MQ, Lin ZJ, Weng N (2013) Applications of high-resolution MS in bioanalysis. *Bioanalysis* 5:1269-1276
67. Meyer MR (2013) Do we need high-resolution MS in forensic and clinical toxicology? *Bioanalysis* 5:1161-1163
68. Meyer MR, Helfer AG, Maurer HH (2014) Current position of high-resolution mass spectrometry for drug quantification in clinical & forensic toxicology [review]. *Bioanalysis* 6:2275-2284
69. Gibbons S (2012) 'Legal highs'--novel and emerging psychoactive drugs: a chemical overview for the toxicologist. *Clin Toxicol (Phila)* 50:15-24

70. Beyer J, Drummer OH, Maurer HH (2009) Herbal Drugs of Abuse. In: Ramawat, K. G. Herbal Drugs: Ethnomedicine to Modern Medicine. Springer, Heidelberg
71. Sharma V, McNeill JH (2009) To scale or not to scale: the principles of dose extrapolation. *Br J Pharmacol* 157:907-921
72. Meyer MR, Peters FT, Maurer HH (2008) The role of human hepatic cytochrome P450 isozymes in the metabolism of racemic 3,4-methylenedioxy-methamphetamine and its enantiomers. *Drug Metab Dispos* 36:2345-2354
73. Meyer MR, Maurer HH (2011) Absorption, distribution, metabolism and excretion pharmacogenomics of drugs of abuse [review]. *Pharmacogenomics* 12:215-233
74. Evans AM (2000) Influence of dietary components on the gastrointestinal metabolism and transport of drugs. *Ther Drug Monit* 22:131-136
75. Zhou SF (2009) Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. *Clin Pharmacokinet* 48:761-804

6. Abbreviations

5-HT	serotonin
ADH	alcohol dehydrogenase
AU	arbitrary units
BM	body mass
CC	column chromatography
CNS	central nervous system
COMT	catechol-O-methyltransferase
CYP	cytochrome P450
DA	dopamine
DM	demethyl
EMA	European Medicines Agency
FDA	US Food and Drug Administration
GC	gas chromatography
HLC	human liver cytosol
HLM	human liver microsomes
HR	high resolution
IR	infrared
IS	internal standard
LC	liquid chromatography
LLE	liquid-liquid extraction
MS	mass spectrometry
NAT	<i>N</i> -acetyltransferase
NMR	nuclear magnetic resonance spectroscopy
PDE	phosphodiesterase

SPE	solid-phase extraction
SULT	sulfotransferase
UGT	uridine diphosphate glucuronyltransferase
UN	United Nations

7. Zusammenfassung

Die vorliegende Dissertation umfasst Untersuchungen zum Metabolismus und Nachweisbarkeit der Alkaloide Glaucin, Mesembrin und Mesembrenon.

Glaucin wurde in der Ratte hauptsächlich zu vier Phase-I-Metaboliten O- und N-desalkyliert und anschließend zu Glucuronide oder Sulfaten konjugiert. Die Phase-I-Metaboliten wurden synthetisiert und deren Struktur mittels NMR-Techniken aufgeklärt. Weitere *in-vitro*-Experimente mit HLM bestätigten die Bildung der Metaboliten im Menschen. Folgende CYP-Isoformen waren an den Reaktionen beteiligt: 1A2, 2C19, 2D6, 3A4 und 3A5. Die resultierenden K_m Werte lagen zwischen 25 - 140 μM und die V_{max} Werte zwischen 0.1 - 1.9 pmol/min/pmol. Der analytische Fokus für die Nachweisbarkeit sollte auf den demethylierten Metaboliten und auf den zugehörigen Glucuroniden und/oder Sulfaten.

Mesembrin und Mesembrenon wurden von der Ratte stark metabolisiert. Beide Alkaloide werden hauptsächlich demethyliert und reduziert. Alle phenolischen Metaboliten werden teilweise als Glucuronide oder Sulfate ausgeschieden. Die Phase-I-Metaboliten konnten in *in-vitro*-Experimenten mit humanen Leberpräparationen belegt werden. Die Demethylierungen des Mesembrins wurden durch folgende CYP isoformen katalysiert 1A2, 2B6, 2C19, 2D6 und 3A4 und die des Mesembrenons durch 2C9, 2C19, 2D6 und 3A4. Der analytische Fokus für die Nachweisbarkeit sollte auf den demethylierten und reduzierten Metaboliten liegen und auf den zugehörigen Glucuroniden und/oder Sulfaten.